Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Current Deferred Revenue (2016 - 2019)

Kiora Pharmaceuticals (KPRX) has disclosed Current Deferred Revenue for 4 consecutive years, with $2.7 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Current Deferred Revenue fell 78.19% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Dec 2018, down 78.19%, and an annual FY2018 reading of $2.7 million, down 78.19% over the prior year.
  • Current Deferred Revenue was $2.7 million for Q4 2018 at Kiora Pharmaceuticals, roughly flat from $2.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $12.3 million in Q4 2017 and bottomed at $1.0 million in Q3 2015.
  • Average Current Deferred Revenue over 4 years is $4.7 million, with a median of $2.8 million recorded in 2018.
  • The sharpest move saw Current Deferred Revenue soared 245.7% in 2017, then tumbled 78.19% in 2018.
  • Year by year, Current Deferred Revenue stood at $1.9 million in 2015, then skyrocketed by 121.49% to $4.2 million in 2016, then skyrocketed by 191.45% to $12.3 million in 2017, then crashed by 78.19% to $2.7 million in 2018.
  • Business Quant data shows Current Deferred Revenue for KPRX at $2.7 million in Q4 2018, $2.7 million in Q3 2018, and $2.7 million in Q2 2018.